Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 8:13:5123-5133.
doi: 10.2147/OTT.S219449. eCollection 2020.

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data

Yazeed Sawalha  1 , Kami Maddocks  1
Affiliations
Review

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data

Yazeed Sawalha et al. Onco Targets Ther. .

Abstract

Abstract: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma.

Methods: We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. We also reviewed the package insert and available abstracts and posters presented at national and international meetings.

Keywords: CD79; antibody-drug conjugate; clinical trials; novel; polatuzumab.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Polatuzumab structure and mechanism of action. Polatuzumab is composed of an anti-CD79b monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a protease-cleavable linker. After binding to CD79b, the complex is internalized by endocytosis and directed to lysosomes where the linker is cleaved and MMAE released to the cytosol. Free MMAE inhibits microtubule formation and results in cell growth arrest and apoptosis. Extracellular MMAE release can occur leading to systemic adverse events.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–2729. doi:10.1182/blood-2009-02-205500 - DOI - PubMed
    1. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol. 2004;41(6–7):599–613. doi:10.1016/j.molimm.2004.04.008 - DOI - PubMed
    1. Chu PG, Arber DA. CD79: a review. Appl Immunohistochem Mol Morphol. 2001;9(2):97–106. doi:10.1097/00129039-200106000-00001 - DOI - PubMed
    1. Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110(2):616–623. doi:10.1182/blood-2007-01-066704 - DOI - PubMed
    1. Busman-Sahay K, Drake L, Sitaram A, Marks M, Drake JR. Cis and trans regulatory mechanisms control AP2-mediated B cell receptor endocytosis via select tyrosine-based motifs. PLoS One. 2013;8(1):e54938. doi:10.1371/journal.pone.0054938 - DOI - PMC - PubMed